Matter Bio Launches Clinical Trial for Novel Pancreatic Cancer Immunotherapy

News related to:Matter Bio · 2 min read
SAN FRANCISCO, Nov. 18, 2026 /CourierPR/ -- Matter Bio, a biotechnology company developing innovative therapies targeting the underlying biology of disease, has initiated a groundbreaking first-in-human clinical trial for a novel immunotherapy designed to combat advanced pancreatic cancer. The therapy, named Lm-LLO-TT, aims to harness the body's existing immune memory against tetanus to target and fight cancer cells.
The Phase 1 study, registered as NCT07828236 on ClinicalTrials.gov, is currently recruiting patients at Montefiore Medical Center in New York. The trial will evaluate the safety, tolerability, and appropriate dosing of Lm-LLO-TT, administered intraperitoneally in combination with low-dose gemcitabine. The study plans to enroll up to 18 patients with previously treated unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC).
Bradley's statement underscores the company's commitment to advancing innovative treatments for a disease that has long posed significant challenges to medical professionals.
The therapy leverages an attenuated strain of Listeria monocytogenes engineered to express a tetanus toxoid antigen. By tapping into the body's existing immune memory against tetanus, the therapy is designed to activate T cells and redirect immune responses toward tumors. This innovative approach represents a departure from traditional immunotherapy methods, which often involve introducing new antigens to the immune system.
The clinical trial is expected to assess preliminary anti-tumor activity and immune responses. The study will provide critical insights into the potential of Lm-LLO-TT as a treatment for advanced pancreatic cancer, a disease that has long posed significant challenges to medical professionals. The trial marks an important milestone for Matter Bio and its subsidiary Loki Therapeutics as it advances its novel immunotherapy platform into clinical development.
Pancreatic cancer remains one of the most difficult cancers to treat, particularly in patients whose disease cannot be surgically removed. Despite advances in treatment, patients with advanced disease continue to face limited therapeutic options. The initiation of this clinical trial is a significant step in the fight against this deadly disease, offering hope to patients and their families.
Matter Bio's focus on developing technologies and therapeutics to address fundamental drivers of disease, with a particular emphasis on genomic integrity and cancer, positions the company at the forefront of biotechnology innovation. The company's commitment to addressing the complexities of pancreatic cancer underscores its dedication to improving patient outcomes and advancing the field of immunotherapy.
The trial is an important first step toward understanding the potential of Lm-LLO-TT for patients with pancreatic cancer. As the study progresses, it will provide valuable data that could pave the way for future treatments and therapies in the fight against this deadly disease. The results of this trial could have far-reaching implications for the broader field of immunotherapy, potentially opening new avenues for the treatment of other challenging cancers as well.